Cuesta ÁM, et al. PLoS One. 2009, 4:e5381. doi: 10.1371/journal.pone.0005381

Sanchez-Martin D, et al.  J. Biol. Chem. 2011, 286:5197-5203. doi: 10.1074/jbc.M110.161927 

Cuesta ÁM, et al. MAbs 2012.. 4:226-32. doi: 10.4161/mabs.4.2.19140

Blanco-Toribio A, et al. MAbs 2013. 5:70-9. doi: 10.4161/mabs.22698

Alvarez-Cienfuegos A, et al. Sci. Rep. 2016. 6:28643. doi: 10.1038/srep28643.

Harwood SL, et al. Oncoimmunology 2018. doi: 10.1080/2162402X.2017.1377874.

Latest News

Leadartis announces the publication "An Fc-free EGFR-specific 4-1BB-agonistic trimerbody displays broad anti-tumor activity in humanized murine cancer models without toxicity” in Clinical Cancer Research
Leadartis reaches a major milestone with the demonstration of absence of toxicity of its drug candidate in preclinical models

Leadartis reaches a major milestone with the demonstration of...

Leadartis featured in EXPANSION as a ‘Start up’ that leads the fight against cancer